Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis

R. Daifuku, Edward A Panacek, K. Haenftling, W. K. Swenson, A. W. Prescott, J. L. Johnson

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

MAB-T88 is a human monoclonal IgM antibody directed at the lipopolysaccharide of gram-negative bacteria. A protocol was designed to identify a group of septic patients with a very high likelihood of gram-negative bacteremia. All 6 patients entered in the protocol had a gram-negative source, and 4 of 6 had gram-negative bacteremia. In this patient population, MAB-T88 was shown to be safe with an effective half-life of 19.1 hours.

Original languageEnglish (US)
Pages (from-to)36-39
Number of pages4
JournalHuman Antibodies and Hybridomas
Volume4
Issue number1
StatePublished - 1993
Externally publishedYes

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis'. Together they form a unique fingerprint.

  • Cite this